-$0.35 Earnings Per Share Expected for Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) This Quarter

Share on StockTwits

Wall Street brokerages predict that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with estimates ranging from ($0.40) to ($0.29). Adaptimmune Therapeutics reported earnings per share of ($0.48) during the same quarter last year, which would suggest a positive year over year growth rate of 27.1%. The firm is scheduled to report its next quarterly earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($1.17) per share for the current financial year, with EPS estimates ranging from ($1.34) to ($0.94). For the next financial year, analysts forecast that the business will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.45) to ($0.83). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%.

A number of equities research analysts recently commented on ADAP shares. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th. ValuEngine lowered shares of Yext from a “strong-buy” rating to a “buy” rating in a report on Friday, May 10th. Svb Leerink lowered shares of Intersect ENT from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $41.00 to $29.00 in a report on Tuesday, May 7th. Citigroup set a $14.00 price target on shares of Coty and gave the company a “hold” rating in a report on Thursday, May 30th. Finally, Roth Capital started coverage on shares of Tcr2 Therapeutics in a report on Friday, May 31st. They set a “neutral” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $6.59.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. D. E. Shaw & Co. Inc. purchased a new position in shares of Adaptimmune Therapeutics in the fourth quarter valued at $1,231,000. Baillie Gifford & Co. raised its holdings in shares of Adaptimmune Therapeutics by 3.8% in the first quarter. Baillie Gifford & Co. now owns 3,839,190 shares of the biotechnology company’s stock valued at $16,508,000 after acquiring an additional 139,669 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Adaptimmune Therapeutics by 1,681,328.6% in the fourth quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 117,693 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at about $622,000. Finally, BlackRock Inc. grew its stake in Adaptimmune Therapeutics by 10.4% in the fourth quarter. BlackRock Inc. now owns 856,415 shares of the biotechnology company’s stock valued at $4,924,000 after purchasing an additional 81,010 shares during the last quarter. 66.30% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ADAP opened at $3.63 on Friday. The firm’s fifty day moving average price is $3.62. Adaptimmune Therapeutics has a 52 week low of $3.20 and a 52 week high of $14.54. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.12. The company has a market cap of $382.12 million, a price-to-earnings ratio of -3.78 and a beta of 1.63.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Story: Understanding Specialty Certificates of Deposit

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Brokerages Expect OncoSec Medical Inc  Will Post Earnings of -$1.37 Per Share
Zacks: Brokerages Expect OncoSec Medical Inc Will Post Earnings of -$1.37 Per Share
First Republic Bank  Receives $103.00 Consensus Price Target from Brokerages
First Republic Bank Receives $103.00 Consensus Price Target from Brokerages
Raymond James  Set to Announce Quarterly Earnings on Wednesday
Raymond James Set to Announce Quarterly Earnings on Wednesday
-$0.35 Earnings Per Share Expected for Adaptimmune Therapeutics PLC –  This Quarter
-$0.35 Earnings Per Share Expected for Adaptimmune Therapeutics PLC – This Quarter
American Airlines Group  Set to Announce Earnings on Thursday
American Airlines Group Set to Announce Earnings on Thursday
Scor  Scheduled to Post Earnings on Thursday
Scor Scheduled to Post Earnings on Thursday


© 2006-2019 Ticker Report